2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cell LineCystadenocarcinoma, SerousDose-Response Relationship, DrugDown-RegulationDrug Resistance, NeoplasmEpothilonesFemaleHumansImmunohistochemistryKaplan-Meier EstimateMicrotubulesNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTaxoidsTubulinTubulin ModulatorsConceptsClass III β-tubulinClear cell carcinomaIII β-tubulinCell carcinomaOverall survivalP-glycoproteinClass III β-tubulin overexpressionClinical outcomesPolymerase chain reactionPaclitaxel resistanceClass III β-tubulin expressionPlatinum/taxane chemotherapyPoor overall survivalSerous papillary carcinomaChain reactionOvarian clear cellFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTime polymerase chain reactionPolymerase chain reaction resultsΒ-tubulin expressionTaxane chemotherapyPoor outcomePoor prognosis
2011
Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody
Santin A, Bellone S, Varughese J, Cocco E, Ratner E, Silasi D, Rutherford T, Schwartz P, Azodi M, Pecorelli S. Uterine serous papillary carcinomas overexpress human trophoblast cell surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Gynecologic Oncology 2011, 120: s6-s7. DOI: 10.1016/j.ygyno.2010.12.018.Peer-Reviewed Original ResearchUterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody
Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody. Cancer 2011, 117: 3163-3172. PMID: 21246534, PMCID: PMC3128671, DOI: 10.1002/cncr.25891.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaPrimary USPC cell linesUSPC cell linesAntibody-dependent cellular cytotoxicitySerous papillary carcinomaTrop-2 expressionReal-time polymerase chain reactionPolymerase chain reactionTrop-2Papillary carcinomaCell linesMonoclonal antibodiesChemotherapy-resistant variantsNatural killer cytotoxicityStandard treatment modalityUterine serous carcinomaComplement-dependent cytotoxicityNovel therapeutic strategiesNovel therapeutic agentsKiller cytotoxicityEndometrial cancerSerous carcinomaTreatment modalitiesControl antibodyHRS7
2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma
Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal Of Cancer 2010, 103: 812-819. PMID: 20700124, PMCID: PMC2966612, DOI: 10.1038/sj.bjc.6605760.Peer-Reviewed Original ResearchConceptsUSPC cell linesInterleukin-2Tissue factorTF expressionReal-time PCRFactor VIILow HER2/neu expressionCell linesLow dosesPrimary USPC cell linesDependent cell-mediated cytotoxicityUterine serous papillary carcinomaHER2/neu expressionTargeting tissue factorSerous papillary adenocarcinomaStandard treatment modalityCell-mediated cytotoxicityTreatment of patientsNormal endometrial cellsSerous papillary carcinomaNovel therapeutic agentsType II receptorAdenocarcinoma cell lineEndometrial cancerAggressive variantHigher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro
Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, Siegel EE, Richter CE, Schwartz PE, Rutherford TJ, Santin AD. Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecologic Oncology 2010, 119: 140-145. PMID: 20673976, PMCID: PMC2939197, DOI: 10.1016/j.ygyno.2010.06.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1Carcinoma, PapillaryCell Line, TumorCystadenocarcinoma, SerousDose-Response Relationship, DrugDrug Screening Assays, AntitumorEpothilonesFemaleHumansPaclitaxelReceptor, ErbB-2TubulinUterine NeoplasmsConceptsLow HER-2/neu expressionHER-2/neu expressionPrimary USPC cell linesUSPC cell linesUterine serous papillary carcinomaSensitivity/resistanceNeu expressionCell linesAggressive endometrial tumorsPromising novel drugSerous papillary carcinomaΒ-tubulin IIIQuantitative RT-PCRPaclitaxel chemotherapyAdverse prognosisCarcinoma cell linesEndometrial tumorsNeu overexpressionPapillary carcinomaUSPC patientsPatupilonePapillary carcinoma cell lineP-glycoproteinNovel drugsPaclitaxelOverexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)
El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Rüttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201). Molecular Cancer Therapeutics 2010, 9: 57-66. PMID: 20053761, PMCID: PMC2806489, DOI: 10.1158/1535-7163.mct-09-0675.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntigens, NeoplasmCarcinoma, PapillaryCell Adhesion MoleculesCell Line, TumorCell MembraneCystadenocarcinoma, SerousDrug Resistance, NeoplasmDrug Screening Assays, AntitumorEpithelial Cell Adhesion MoleculeFemaleFlow CytometryGene Expression Regulation, NeoplasticHumansImmunoglobulin GImmunohistochemistryImmunotherapyInterleukin-2Killer Cells, NaturalMiddle AgedNeoplasm MetastasisRNA, MessengerUterine NeoplasmsConceptsUterine serous papillary carcinomaUSPC cell linesNormal endometrial cellsPrimary USPC cell linesAntibody-dependent cellular cytotoxicitySerous papillary carcinomaCellular cytotoxicityPapillary carcinomaCell linesFlow cytometryAdvanced/recurrentStandard treatment modalityCell-dependent cytotoxicityUterine serous carcinomaComplement-dependent cytotoxicitySurface expressionHuman monoclonal antibodyNovel therapeutic strategiesFresh frozen biopsiesHigh surface expressionEpithelial cell adhesion moleculeOverexpression of EpCAMParaffin-embedded tissuesMedian copy numberSerous carcinoma
2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. British Journal Of Cancer 2009, 101: 335-341. PMID: 19536090, PMCID: PMC2720219, DOI: 10.1038/sj.bjc.6605129.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerum amyloid AUSPC patientsBenign diseaseSAA concentrationsNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerSerum SAALiver-secreted proteinsNormal healthy femalesUSPC cell linesEarly disease recurrenceSerous papillary carcinomaNormal endometrial tissuesExpression levelsProtein expression levelsEndometrial cancerAggressive variantHealthy womenEndometrial tissuePapillary cancerSerum biomarkersAmyloid AHealthy groupPotential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma
Santin A, Bellone S, El-Sahwi K, Buza N, Tavassoli F, Silasi D, Azodi M, Schwartz P, Rutherford T, Pecorelli S. Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma. Journal Of Clinical Oncology 2009, 27: e16502-e16502. DOI: 10.1200/jco.2009.27.15_suppl.e16502.Peer-Reviewed Original ResearchUterine serous papillary carcinomaPrimary USPC cell linesAntibody-dependent cellular cytotoxicityUSPC cell linesNormal endometrial cellsSerous papillary carcinomaComplement-dependent cytotoxicityHuman monoclonal antibodyEpithelial cell adhesion moleculeEndometrial cellsCell adhesion moleculePapillary carcinomaTherapeutic strategiesCell linesChromium release cytotoxicity assaysFlow cytometryEpCAM expressionMonoclonal antibodiesDependent cytotoxicityAdhesion moleculesRelease cytotoxicity assayStandard treatment modalityDependent cellular cytotoxicityUterine serous carcinomaAggressive biologic behaviorDevelopment and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas
Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD. Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. American Journal Of Obstetrics And Gynecology 2009, 201: 70.e1-70.e9. PMID: 19426958, PMCID: PMC3701950, DOI: 10.1016/j.ajog.2009.02.010.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, PapillaryCell Line, TumorCell SeparationClaudin-3Enzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene LibraryHumansImmunoglobulin FragmentsMembrane ProteinsMicroscopy, ConfocalOvarian NeoplasmsSelf-Sustained Sequence ReplicationSensitivity and SpecificitySurface Plasmon ResonanceUterine Cervical NeoplasmsConceptsClaudin-3Uterine serous carcinoma cell linesSerous papillary carcinomaHuman antibody phage display libraryNovel therapeutic targetEnzyme-linked immunosorbent assayEnzyme-linked immunosorbentHuman single-chain antibody fragmentAntibody phage display libraryCarcinoma cell linesUterine carcinomaNovel antitumor agentsPapillary carcinomaTherapeutic targetSingle-chain antibody fragmentHuman antibodiesHuman malignanciesImmunosorbent assayConformational epitopesPhage display libraryCarcinomaCell linesSurface immunofluorescenceCell surface immunofluorescenceAntitumor agents
2007
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes
Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. American Journal Of Obstetrics And Gynecology 2007, 196: 245.e1-245.e11. PMID: 17346539, DOI: 10.1016/j.ajog.2006.10.874.Peer-Reviewed Original ResearchConceptsMetastasis-associated genesGene expressionOverexpression of CXCL12Gene expression profilesGene expression profilingMetastatic ovarian cancerNumber of invasionsHepsin geneHuman genesExpression profilingExpression profilesOligonucleotide microarraysQuantitative real-time polymerase chain reactionOvarian cancerGenesProbe setsPrimary ovarian serous carcinomaOvarian serous papillary carcinomaSerous papillary ovarian carcinomasProtein levelsSerous papillary carcinomaReal-time polymerase chain reactionOvarian serous carcinomaOspCPredictive genesOverexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma
Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma. Cancer 2007, 109: 1312-1322. PMID: 17326053, DOI: 10.1002/cncr.22536.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsClaudin-3Claudin-4Clostridium perfringensCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Resistance, NeoplasmEnterotoxinsFemaleGene ExpressionHumansInjections, IntraperitonealMembrane ProteinsMiceMice, SCIDMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUp-RegulationUterine Cervical NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous papillary carcinomaClaudin-4 receptorsUSPC cell linesSerous papillary carcinomaClaudin-3Endometrial cancerPapillary carcinomaClaudin-4 protein expressionChemotherapy-resistant variantsCytotoxic Clostridium perfringensSublethal intraperitoneal injectionsReverse transcriptase-polymerase chain reactionQuantitative reverse transcriptase-polymerase chain reactionTumor cell necrosisSCID mouse xenograftsType-specific therapiesDose-dependent cytotoxic effectCell linesTight junction proteinsControl tissue samplesHigh-affinity receptorAggressive variantTumor disappearanceIntraperitoneal injectionPolymerase chain reaction
2006
0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin
Santin A, Bandiera E, Comper F, Bellone M, Marizzoni S, Zanolini A, Palmieri M, Siegel E, Mckinney J, Thomas M, Hennings L, Roman J, Burnett A, Cannon M, Pecorelli S. 0047: Claudin-3 and Claudin-4 Receptor Overexpression: Novel Targets for a Type Specific Therapy Against Uterine Serous Papillary Carcinomas Using Clostridium Perfringens Enterotoxin. International Journal Of Gynecological Cancer 2006, 16: 612.2-612. DOI: 10.1136/ijgc-00009577-200610001-00047.Peer-Reviewed Original ResearchOverexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas
Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. American Journal Of Obstetrics And Gynecology 2006, 194: 1296-1302. PMID: 16647913, DOI: 10.1016/j.ajog.2005.10.794.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaSerous papillary carcinomaPapillary carcinoma patientsCarcinoma patientsEndometrioid carcinomaPapillary carcinomaKallikrein 10Benign diseaseSecretion levelsEndometrioid carcinoma patientsNormal healthy femalesTumor culturesSerous papillary tumorsCell biopsyPrimary endometrioid carcinomaNon-cancer groupExpression levelsReal-time polymerase chain reactionGene expression levelsPrimary tumor culturesAggressive variantHealthy womenCarcinoma cell linesPapillary tumorsEndometrial tumors
2005
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecologic Oncology 2005, 98: 92-98. PMID: 15904949, DOI: 10.1016/j.ygyno.2005.03.016.Peer-Reviewed Original ResearchConceptsUterine serous papillary carcinomaIL-6 gene expression levelsEndometrioid carcinomaInterleukin-6Primary endometrioid carcinomaEnzyme-linked immunosorbent assayEndometrial carcinomaHealthy femalesUSPC patientsMean serum IL-6 levelPrimary USPC cell linesIL-6 serum concentrationsSerum IL-6 levelsAnti-tumor immune functionBenign abdominal diseasesChemotherapy-resistant variantsControl endometrial cellsNormal healthy femalesSerous papillary histologyUSPC cell linesIL-6 concentrationsIL-6 levelsBenign disease patientsHigher serum levelsSerous papillary carcinomaHuman Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer. Clinical Cancer Research 2005, 11: 3320-3325. PMID: 15867230, DOI: 10.1158/1078-0432.ccr-04-2528.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousEndometrial NeoplasmsEnzyme-Linked Immunosorbent AssayFemaleGene Expression Regulation, NeoplasticHumansKallikreinsMiddle AgedReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaSerous papillary carcinomaEndometrioid carcinomaUSPC patientsBenign diseasePapillary carcinomaNovel biomarkersPrimary USPC cell linesUterine serous papillary cancerOvarian serous papillary carcinomaEndometrioid carcinoma patientsNormal healthy femalesUSPC cell linesEarly disease recurrenceNormal endometrial cellsPotential serum biomarkersPrimary endometrioid carcinomaNew Potential Serum BiomarkerExpression levelsGene expression levelsHK6 proteinEndometrial biopsyCarcinoma patientsDisease recurrenceEndometrial cancerGene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Santin AD, Zhan F, Cane' S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman JJ, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal Of Cancer 2005, 92: 1561-1573. PMID: 15785748, PMCID: PMC2362016, DOI: 10.1038/sj.bjc.6602480.Peer-Reviewed Original ResearchConceptsUterine serous papillary cancerNormal endometrial cellsEndometrial cancerAggressive variantClaudin-4Normal endometrial epithelial cellsUterine serous papillary carcinomaAdhesion moleculesNovel therapeutic markerCommon gynecologic tumorsSerous papillary carcinomaParaffin-embedded specimensEndometrial epithelial cellsL1 cell adhesion moleculeType-specific therapiesRas homolog gene familyQuantitative RT-PCRScalar dosesGynecologic tumorsPapillary cancerEndometrial cellsInterleukin-6Cell adhesion moleculeNovel molecular markersPapillary carcinoma
2004
GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY
Santin A, Bellone S, Cane' S, Palmieri M, Bignotti E, Anfossi S, Thomas M, Roman J, Kay H, Burnett A, O'Brien T, Cannon M, John S, Zhan F, Tian E, Pecorelli S. GENE EXPRESSION FINGERPRINT OF UTERINE SEROUS PAPILLARY CARCINOMA: IDENTIFICATION OF NOVEL MOLECULAR MARKERS FOR UTERINE SEROUS CANCER DIAGNOSIS AND THERAPY. International Journal Of Gynecological Cancer 2004, 14: 2.3-2. DOI: 10.1136/ijgc-00009577-200409001-00006.Peer-Reviewed Original ResearchDiscrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British Journal Of Cancer 2004, 90: 1814-1824. PMID: 15208622, PMCID: PMC2409747, DOI: 10.1038/sj.bjc.6601791.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, PapillaryCells, CulturedCystadenocarcinoma, SerousDiagnosis, DifferentialFemaleFlow CytometryGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedOligonucleotide Array Sequence AnalysisOvarian NeoplasmsReceptor, ErbB-2Reverse Transcriptase Polymerase Chain ReactionUterine NeoplasmsConceptsUterine serous papillary carcinomaGene expressionOverexpressed genesSerous papillary carcinomaGene expression fingerprintGene expression profilingHuman genesC-erbB2 geneExpression fingerprintsMolecular basisExpression profilingPapillary carcinomaOligonucleotide microarraysExpression productsQuantitative RT-PCRGenesClinical tissue samplesProbe setsTwo-fold differenceMore effective treatment modalitiesEffective treatment modalitySerous papillary tumorsPlasminogen activator inhibitorDifferent biological behaviorDevelopment of novel
2002
Overexpression of HER-2/neu in uterine serous papillary cancer.
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clinical Cancer Research 2002, 8: 1271-9. PMID: 12006548.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsBreast NeoplasmsCell DivisionCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousFemaleFlow CytometryHumansImmunohistochemistryInterleukin-2Killer Cells, NaturalMiddle AgedNeoplasm StagingOvarian NeoplasmsReceptor, ErbB-2RituximabTrastuzumabTumor Cells, CulturedUterine NeoplasmsConceptsUterine serous papillary carcinomaAntibody-dependent cellular cytotoxicityUSPC cell linesIntensity of expressionOvarian cancerPrimary USPC cell linesUterine serous papillary cancerCell linesFlow cytometryHigh-grade ovarian cancerOvarian cancer cell linesSerous papillary carcinomaCell proliferationComplement-dependent cytotoxicityComplement-mediated cytotoxicityAttractive therapeutic strategyHuman serum IgGCancer cell linesEndometrial cancerNatural killerAggressive variantEffector cellsSerum IgGPapillary cancerIL-2